{"filing":{"accession_number":"0001185185-26-004202","cik":"0001903784","ticker":null,"company_name":"Vogenx, Inc.","form":"8-K","filing_date":"2026-09-22","report_date":"2026-09-21","primary_document":"vogenx8k092226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1903784/000118518526004202/vogenx8k092226.htm"},"events":[{"id":34289,"run_id":31556,"accession_number":"0001185185-26-004202","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Ken Toombs was appointed to Vogenx's Board of Directors as a Class II director effective September 21, 2026, with concurrent appointments as Chair of the Audit Committee and member of the Compensation Committee and Nominating and Corporate Governance Committee. This appointment strengthens independent board oversight for the recently IPO'd clinical-stage biopharmaceutical company.","company_name":"Vogenx, Inc.","ticker":null,"filing_date":"2026-09-22","form":"8-K","submitted_at":null,"items":[{"id":37971,"accession_number":"0001185185-26-004202","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ken Toombs to the Board of Directors as a Class II director effective September 21, 2026, with concurrent appointments to the Audit Committee (as Chair), Compensation Committee, and Nominating and Corporate Governance Committee. This is a clear executive appointment event. The appointment is material because it represents a significant governance change for a recently IPO'd clinical-stage biopharmaceutical company (IPO in August 2026), bringing a seasoned executive with three decades of professional services and life sciences leadership experience to strengthen independent board oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:03:42.805772+00:00","company_name":"","ticker":null,"filing_date":""},{"id":37972,"accession_number":"0001185185-26-004202","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ken Toombs to Vogenx's Board of Directors, effective September 21, 2026, with assignment as an independent director and Chair of the Audit Committee. This is a material governance event for a recently IPO'd company (August 2026), as the appointment of a seasoned executive with three decades of professional services and life sciences experience to lead audit oversight strengthens independent oversight during a critical scaling phase post-IPO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:03:42.805772+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":37971,"accession_number":"0001185185-26-004202","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ken Toombs to the Board of Directors as a Class II director effective September 21, 2026, with concurrent appointments to the Audit Committee (as Chair), Compensation Committee, and Nominating and Corporate Governance Committee. This is a clear executive appointment event. The appointment is material because it represents a significant governance change for a recently IPO'd clinical-stage biopharmaceutical company (IPO in August 2026), bringing a seasoned executive with three decades of professional services and life sciences leadership experience to strengthen independent board oversight.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:03:42.805772+00:00","company_name":"Vogenx, Inc.","ticker":null,"filing_date":"2026-09-22"},{"id":37972,"accession_number":"0001185185-26-004202","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"The filing discloses the appointment of Ken Toombs to Vogenx's Board of Directors, effective September 21, 2026, with assignment as an independent director and Chair of the Audit Committee. This is a material governance event for a recently IPO'd company (August 2026), as the appointment of a seasoned executive with three decades of professional services and life sciences experience to lead audit oversight strengthens independent oversight during a critical scaling phase post-IPO.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-22T20:03:42.805772+00:00","company_name":"Vogenx, Inc.","ticker":null,"filing_date":"2026-09-22"}]}